Agnes Mwakingwe-Omar, MD, PhD

GSK, Rockville, MD, USA

Disclosure(s): GSK: Employed, Stocks/Bonds (Private Company)

Poster(s):

• (P-19) The Adjuvanted Recombinant Zoster Vaccine Is Effective in Preventing Herpes Zoster (HZ) Among Patients ≥ 50 Years of Age (YOA) With Selected Autoimmune Diseases in the United States: A Real-World Database Analysis (2018–2021)
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-112) Characterization of Herpes Zoster Cases and Sustained High Vaccine Efficacy Against Herpes Zoster Complications in Individuals Vaccinated with Recombinant Zoster Vaccine During A Long-Term Follow-Up Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-2345) Recent Incidence Rate of Herpes Zoster Among Immunocompetent Adults Aged 18 and Older in the United States
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT